New treatment for psoriasis

A new therapy has approved by the TGA for treatment of adults with moderate to severe plaque psoriasis Tremfya (guselkumab) is the first biologic approved in Australia that selectively blocks interleukin (IL)-23, a cytokine that plays a critical role in the pathogenesis of plaque psoriasis. Its approval by the TGA is based on clinical program